PMID- 35533253
OWN - NLM
STAT- MEDLINE
DCOM- 20220511
LR  - 20220716
IS  - 1526-2359 (Electronic)
IS  - 1073-2748 (Print)
IS  - 1073-2748 (Linking)
VI  - 29
DP  - 2022 Jan-Dec
TI  - Upregulation of PKN1 as a Prognosis Biomarker for Endometrial Cancer.
PG  - 10732748221094797
LID - 10.1177/10732748221094797 [doi]
LID - 10732748221094797
AB  - BACKGROUND: Several markers of survival among endometrial cancer (EC) patients 
      have been proposed, namely, the oncoprotein stathmin, RAF kinase inhibitor 
      (RKIP), Cyclin A, GATA-binding protein 3 (GATA3), and growth and differentiation 
      factor-15 (GDF-15). Their elevated expression correlated significantly with a 
      high stage, serous papillary/clear cell subtypes, and aneuploidy. In a previous 
      study, we reported the elevated expression of the serine/threonine protein kinase 
      N1 (PKN1) in cancerous cells. In the present paper, we studied PKN1 expression in 
      EC tissues from a large cohort of patients, to determine whether PKN1 can serve 
      as a marker for the aggressiveness and prognosis of EC, and/or as a marker of 
      survival among EC patients. METHODS: Tissue samples from EC patients were 
      examined retrospectively for tumor type, tumor size, FIGO stage and grade, depth 
      of invasion in the myometrium, and presence of lymph node metastasis. The PKN1 
      protein expression in EC cells was assessed by immunohistochemistry. PKN1 mRNA 
      levels were analyzed in publicly available databases, using bioinformatic tools. 
      RESULTS: We found that expression of PKN1 at the mRNA and proteins levels tended 
      to increase in high-grade EC samples (P = .0001 and P = .06, respectively). In 
      addition, patients with metastatic disease had higher PKN1 mRNA levels (P = .02). 
      Moreover, patients with high PKN1 expression could be characterized by poorer 
      survival. CONCLUSIONS: We have shown a trend of the higher PKN1 expression levels 
      in EC patients with poor prognosis. Therefore, PKN1 might be considered as a 
      candidate prognostic marker for EC.
FAU - Govorov, Igor
AU  - Govorov I
AUID- ORCID: 0000-0003-1809-0270
AD  - Department of Women's and Children's Health, Division of Obstetrics and 
      Gynecology, Karolinska University Hospital, Solna, 27106Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Attarha, Sanaz
AU  - Attarha S
AD  - Science for Life Laboratory, 27106Karolinska Institutet, Stockholm, Sweden.
FAU - Kovalevska, Larysa
AU  - Kovalevska L
AD  - 123495R. E. Kavetsky Institute of Experimental Pathology, Oncology and 
      Radiobiology of NASU.
FAU - Andersson, Emil
AU  - Andersson E
AD  - Department of Women's and Children's Health, Division of Obstetrics and 
      Gynecology, Karolinska University Hospital, Solna, 27106Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Kashuba, Elena
AU  - Kashuba E
AUID- ORCID: 0000-0001-7001-4035
AD  - 123495R. E. Kavetsky Institute of Experimental Pathology, Oncology and 
      Radiobiology of NASU.
AD  - Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum, 
      27106Karolinska Institute, Stockholm, Sweden.
FAU - Mints, Miriam
AU  - Mints M
AD  - Department of Women's and Children's Health, Division of Obstetrics and 
      Gynecology, Karolinska University Hospital, Solna, 27106Karolinska Institutet, 
      Stockholm, Sweden.
AD  - School of Medical Science, Faculty of Medicine and Health, 6233Orebro University, 
      Orebro, Sweden.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Control
JT  - Cancer control : journal of the Moffitt Cancer Center
JID - 9438457
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.1.- (protein kinase N)
RN  - EC 2.7.11.13 (Protein Kinase C)
SB  - IM
MH  - *Biomarkers, Tumor/genetics/metabolism
MH  - *Endometrial Neoplasms/genetics/metabolism/pathology
MH  - Female
MH  - Humans
MH  - Prognosis
MH  - Protein Kinase C
MH  - RNA, Messenger
MH  - Retrospective Studies
MH  - Up-Regulation
PMC - PMC9092572
OTO - NOTNLM
OT  - PKN1
OT  - endometrial cancer
OT  - prognostic marker
OT  - survival
OT  - tumor progression
COIS- Declaration of conflicting interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2022/05/10 06:00
MHDA- 2022/05/12 06:00
PMCR- 2022/05/09
CRDT- 2022/05/09 14:35
PHST- 2022/05/09 14:35 [entrez]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/05/12 06:00 [medline]
PHST- 2022/05/09 00:00 [pmc-release]
AID - 10.1177_10732748221094797 [pii]
AID - 10.1177/10732748221094797 [doi]
PST - ppublish
SO  - Cancer Control. 2022 Jan-Dec;29:10732748221094797. doi: 
      10.1177/10732748221094797.